TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$584.78 Million


Follow-on Offering

Bookrunner, July 2021


Natera, Inc. (“Natera” or the “Company”) is a diagnostics company with proprietary molecular and bioinformatics technology. The mission of the company is to change the management of disease worldwide with a focus on women’s health, oncology, and organ health. The Company offers proprietary, genetic, non-invasive tests to evaluate risk, thus enabling early-detection of prenatal and oncology conditions. The use of blood-based diagnostic tests requires the measurement of very small amounts of relevant genetic material circulating within a much larger blood sample. Natera’s approach combines proprietary molecular biology and computational techniques to measure genomic variations in tiny amounts of DNA, as small as a single cell. Natera has a comprehensive suite of products in the women’s health space, as well as products in oncology and in organ health.